GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Cells, Journal Year: 2023, Volume and Issue: 12(9), P. 1309 - 1309

Published: May 4, 2023

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer’s disease (AD). Although amyloid-β peptide (Aβ) tau are primarily blood biomarkers, recent studies identified other reliable candidates that can serve as measurable indicators pathological conditions. One such candidate is glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal be detected in samples. Increasing evidence suggests GFAP levels used to detect early-stage AD. In this systematic review meta-analysis, we aimed evaluate peripheral a biomarker AD provide overview regarding its utility. Our analysis revealed level was higher Aβ-positive group than negative groups, individuals with or mild cognitive impairment (MCI) compared healthy controls. Therefore, believe clinical use measurements has potential accelerate diagnosis improve prognosis

Language: Английский

---

Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: May 13, 2024

Peripheral glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are sensitive markers of neuroinflammation neuronal damage. Previous studies with highly selected participants have shown that peripheral GFAP NfL levels elevated in the pre-clinical phase Alzheimer's disease (AD) dementia. However, predictive value for dementia requires more evidence from population-based cohorts.

Language: Английский

---

Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study

Journal of Neuroinflammation, Journal Year: 2023, Volume and Issue: 20(1)

Published: July 20, 2023

Dementia is a prevalent non-motor manifestation among individuals with advanced Parkinson's disease (PD). Glial fibrillary acidic protein (GFAP) an inflammatory marker derived from astrocytes. Research has demonstrated the potential of plasma GFAP to forecast progression dementia in PD patients mild cognitive impairment (PD-MCI). However, predictive role cerebrospinal fluid (CSF) on future transformation and alterations Alzheimer's (AD)-associated CSF biomarkers newly diagnosed not been investigated.210 de novo Progression Markers Initiative were recruited. Cognitive participants was evaluated using Cox regression. Cross-sectional longitudinal associations between baseline function AD-related multiple linear regression generalized mixed model.At baseline, mean age 60.85 ± 9.78 years, including 142 normal cognition (PD-NC) 68 PD-MCI patients. The average follow-up time 6.42 1.69 years. A positive correlation observed (β = 0.918, p < 0.001). There no statistically significant difference levels PD-NC groups. Higher predicted greater global decline over early (Montreal Assessment, β - 0.013, 0.014). Furthermore, showed that high associated risk developing 8-year period group (adjusted HR 3.070, 95% CI 1.119-8.418, 0.029). In addition, positively correlated changes only α-synuclein 0.313, 0.001), but also AD, namely, amyloid-β 42 0.147, 0.034), total tau 0.337, 0.001) phosphorylated 0.408, 0.001).CSF may be valuable prognostic tool can predict severity deterioration, accompanied AD-associated pathological markers PD.

Language: Английский

---

The link between gut microbiome and Alzheimer's disease: From the perspective of new revised criteria for diagnosis and staging of Alzheimer's disease

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(8), P. 5771 - 5788

Published: June 28, 2024

Abstract Over the past decades, accumulating evidence suggests that gut microbiome exerts a key role in Alzheimer's disease (AD). The Association Workgroup is updating diagnostic criteria for AD, which changed profiles and categorization of biomarkers from “AT(N)” to “ATNIVS.” Previously, most studies focus on correlation between amyloid beta deposition (“A”), initial AD pathological feature triggering “downstream” tauopathy neurodegeneration. However, limited research investigated interactions other pathogenesis (“TNIVS”). In this review, we summarize current findings microbial characteristics whole spectrum AD. Then, describe association with updated biomarker categories pathogenesis. addition, outline microbiome‐related therapeutic strategies Finally, discuss issues field future directions. Highlights new revised (AD) proposed by have associations are described. Current summarized. Therapeutic based proposed.

Language: Английский

---

Fluid biomarkers for the diagnosis of neurodegenerative diseases

Biomarkers in Neuropsychiatry, Journal Year: 2023, Volume and Issue: 8, P. 100062 - 100062

Published: March 23, 2023

In this review, we evaluate the role of fluid biomarkers related to neurodegenerative diseases. Such conditions present diagnostic challenges due phenotypic heterogeneity, longitudinal evolution, overlap between entities, and variability in progression. Biomarkers can potentially provide insight into diagnosis, progression, prognostication, treatment efficacy. This review covers recent advances including beta-amyloid, tau protein, neurofilament light chain, alpha-synuclein glial fibrillary briefly touches upon imaging biomarkers. For each biomarker, discuss pathophysiological correlates, clinical uses, accuracy, limitations.

Language: Английский

---

Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population

Clinical Biochemistry, Journal Year: 2023, Volume and Issue: 121-122, P. 110680 - 110680

Published: Oct. 24, 2023

Language: Английский

---

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 3057 - 3057

Published: Feb. 3, 2023

Autism spectrum disorder (ASD) is one of the most common neurodevelopment disorders, characterized by a multifactorial etiology based on interaction genetic and environmental factors. Recent evidence supports neurobiological hypothesis neuroinflammation theory. To date, there are no sufficiently validated diagnostic prognostic biomarkers for ASD. Therefore, we decided to investigate potential role ASD two well known other neurological inflammatory conditions: glial fibrillary acidic protein (GFAP) neurofilament (Nfl). Nfl GFAP serum levels were analyzed using SiMoA technology in group patients healthy control (CTRS), age- gender-matched. Then investigated distribution, frequency, correlation between clinical data among group. The comparison children showed mean value these markers significantly higher (sNfL pt 6.86 pg/mL median 5.7 pg/mL; CTRS 3.55 3.1 pg; 205.7 155.4 77.12 63.94 pg/mL). Interestingly, also found statistically significant positive hyperactivity symptoms (p-value <0.001). Further investigations larger groups necessary confirm our verify more depth features, such as severity core symptoms, presence associated and/or evaluation therapeutic intervention. However, not only might shed light neurobiology ASD, supporting neurodegeneration hypothesis, but they support use early diagnosis longitudinally monitor disease activity, even future biomarkers.

Language: Английский

---

Association between Modifiable Risk Factors and Levels of Blood-Based Biomarkers of Alzheimer’s and Related Dementias in the Look AHEAD Cohort

Journal of Aging Research and Lifestyle, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

BACKGROUND: Emerging evidence suggests that a number of factors can influence blood-based biomarker levels for Alzheimer's disease (AD) and related dementias (ADRD).We examined the associations demographic clinical characteristics have with AD/ADRD in an observational continuation trial cohort older individuals type 2 diabetes overweight or obesity.METHODS: Participants aged 45-76 years were randomized to 10-year Intensive Lifestyle Intervention (ILI) support education (DSE) condition.Stored baseline end intervention (8-13 later) plasma samples analyzed Quanterix Simoa HD-X Analyzer.Changes Aβ42, Aβ40, Aβ42/Aβ40, ptau181, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) evaluated relation randomization status, demographic, characteristics.RESULTS: In sample 779 participants from Look AHEAD cohort, we found significant between biomarkers 15 18 (age, gender, race ethnicity, education) (APOE, depression, alcohol use, smoking, body mass index, HbA1c, duration, treatment, estimated glomerular filtration rate, hypertension, history cardiovascular disease) .CONCLUSIONS: Blood-based are influenced by common characteristics.These should be considered carefully when interpreting these blood values research purposes.

Language: Английский

---

Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury

Journal of Neurology, Journal Year: 2024, Volume and Issue: 271(6), P. 3512 - 3526

Published: March 27, 2024

Abstract Background Definitions of aggressive MS employ clinical and MR imaging criteria to identify highly active, rapidly progressing disease courses. However, the degree overlap between radiological parameters biochemical markers CNS injury is not fully understood. Aim this cross-sectional study was match hallmarks serum/CSF neuroaxonal astroglial (neurofilament light chain (sNfL, cNfL), glial fibrillary acidic protein (sGFAP, cGFAP)). Methods We recruited 77 patients with relapsing–remitting (RRMS) 22 clinically isolated syndrome. NfL GFAP levels in serum CSF were assessed using a single-molecule-array HD-1-analyzer. A general linear model each biomarker as dependent variable computed. Clinical MS, recently proposed by ECTRIMS Consensus Group, modeled independent variables. Other demographic, or laboratory parameters, covariates. Analyses repeated homogenous subgroup, consisting only newly diagnosed, treatment-naïve RRMS presenting an acute relapse. Results After adjusting for covariates multiplicity testing, sNfL cNfL concentrations strongly associated presence ≥2 gadolinium-enhancing lesions ( p = 0.00008; 0.004) well infratentorial on MRI 0.0003; < 0.004). No other correlated significantly CSF. In more homogeneous still 0.001), than 20 T2-lesions 0.049) 0.034), while 0.011) 0.029). Conclusions Among risk factors course, findings but characteristics marker should be given appropriate weight considering prognosis therapy. significant correlation detected alone.

Language: Английский

---

Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms

Journal of the Neurological Sciences, Journal Year: 2022, Volume and Issue: 439, P. 120324 - 120324

Published: June 17, 2022

Language: Английский

---